EUCTR2020-001048-24-LT进行中（未招募）1 期
A multinational, open-label, randomised, controlled trial to investigate efficacy and safety of NNC0365-3769 (Mim8) in adults and adolescents with haemophilia A with or without inhibitors.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 230
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial
- •- Male or female with diagnosis of congenital haemophilia A of any severity based on medical records
- •- Patient has been prescribed, or in need of, treatment with factor VIII or bypassing agent in the last 26 weeks prior to screening
- •- Age above or equal to 12 years at the time of signing informed consent. Germany, Japan and Taiwan: Local requirements apply
- •- Body weight above or equal to 30 kg
- •- Applicable to patients on emicizumab prophylaxis: patient is willing to discontinue emicizumab at the time of screening
- •- Applicable to patients treated with no prophylaxis prior to enrolment: 5 or more bleeds in the last 26 weeks prior to screening visit
- •- Applicable to patients with FVIII activity above 1% who are on prophylactic treatment: 1 or more bleeds in the last 26 weeks prior to screening visit
- •- Willingness and ability to comply with scheduled visits and study procedures, including the completion of diary and patient-reported outcomes questionnaires
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 30
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 190
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •- Previous participation in this trial. Participation is defined as signed informed consent
- •- Participation in any clinical trial of an approved or non-approved investigational medicinal product, within 30 days (or 5 half-lives of the investigational medicinal product, whichever is greater) before screening
- •- Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using a highly effective contraceptive method (highly effective contraceptive measures as defined in the protocol or as required by local regulation or practice). Breast feeding is allowed only during the run-in period
- •- Any disorder, except for conditions associated with haemophilia A, which in the investigator’s opinion might jeopardise subject’s safety or compliance with the protocol
- •- Known or suspected hypersensitivity to trial product(s), any constituents of the product or to related products
- •- Receipt of gene therapy at any given time point
- •- Ongoing or planned immune tolerance induction (ITI) therapy
- •- Major surgery planned at the time of screening
- •- Known congenital or acquired coagulation disorders other than haemophilia A
- •- Hepatic dysfunction defined as aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) above 3 times the upper limit combined with total bilirubin above 1.5 times the upper limit measured at screening
- •- Renal impairment defined as estimated Glomerular Filtration Rate (eGFR) below or equal to 30 ml/min/1.73 m^2 for serum creatinine measured at screening
- •- Previous or current thromboembolic disease or events (includes arterial and venous thrombosis including myocardial infarction, thrombotic microangiography (TMA), pulmonary embolism, cerebral infarction/thrombosis, deep vein thrombosis, other clinically significant thromboembolic events and peripheral artery occlusion) (with the exception of previous catheter-associated thrombosis for which anti-thrombotic treatment is not currently ongoing) or risk of thromboembolic disease, as evaluated by investigator
- •- Mental incapacity, unwillingness to cooperate, or a language barrier precluding adequate understanding and cooperation
- •- Other conditions (e.g. autoimmune disease) or laboratory abnormality that may increase risk of bleeding or thrombosis as evaluated by the investigator
研究者
相似试验
进行中（未招募）
1 期
A research study investigating Mim8 in adults and adolescents with haemophilia A with or without inhibitorsHaemophilia A Haemophilia A with inhibitorsMedDRA version: 20.0Level: LLTClassification code 10018938Term: Haemophilia A (Factor VIII)System Organ Class: 100000004850MedDRA version: 20.0Level: LLTClassification code 10053751Term: Hemophilia A with anti factor VIIISystem Organ Class: 100000004850EUCTR2020-001048-24-SKovo Nordisk A/S247
进行中（未招募）
1 期
A research study investigating Mim8 in adults and adolescents with haemophilia A with or without inhibitorsHaemophilia A Haemophilia A with inhibitorsMedDRA version: 20.0Level: LLTClassification code 10018938Term: Haemophilia A (Factor VIII)System Organ Class: 100000004850MedDRA version: 20.0Level: LLTClassification code 10053751Term: Hemophilia A with anti factor VIIISystem Organ Class: 100000004850EUCTR2020-001048-24-DKovo Nordisk A/S244
进行中（未招募）
3 期
A multinational, open-label, randomised, controlled study to investigate efficacy and safety of NNC0365-3769 (Mim8) in adults and adolescents with haemophilia A with or without inhibitors(NN7769-4514)haemophilia A with or without FVIII inhibitorsJPRN-jRCT2031210643Esaki Risa272
进行中（未招募）
1 期
A research study investigating Mim8 in adults and adolescents with haemophilia A with or without inhibitorsEUCTR2020-001048-24-DEovo Nordisk A/S247
尚未招募
3 期
A research study investigating Mim8 in adults and adolescents with haemophilia A with or without inhibitorsCTRI/2023/02/049474ovo Nordisk AS